Company reports & presentations
ASX Report - Quarterly
ASX Report - Annual
ASX Report - Half-Yearly
Response to COVID-19
Company news and Investor Presentations
30 June 2020
Financial year end
31 August 2020
Full year results
31 December 2020
Half year end
28 February 2021
Half year end results
Genetic Technologies Limited and its Board are committed to achieving and demonstrating the highest standards of corporate governance. The Board continues to review its corporate governance framework and practices to ensure they meet the interests of shareholders.
The Company and its controlled entities together are referred to as the “Group” in this statement.
Reference is made to the revised Corporate Governance Principles and Recommendations issued and revised from time to time by the ASX Corporate Governance Council. The Board believes that all concepts of the revised Principles and Recommendations have been satisfied, however the Board is realistic with respect to the relative size and nature of the Company and have implemented the Recommendations accordingly. The Company endeavours to ensure exceptions to the guidelines do not have negative impact on the best interests of shareholders.
While in most respects the Company complies with the Recommendations, it is recognised that the development and implementation of policies and practices is an ongoing process that evolves with the needs of the business and its stakeholders.
A description of the Group’s main corporate governance practices is set out below. All of these practices, unless otherwise stated, were in place for the entire year.
ASX share information
The Company has 2,435,282,724 ordinary shares on issue. The Company’s ordinary shares are publicly traded on the Australian Securities Exchange (“ASX”) under the symbol GTG. The Company’s share register is maintained by Computershare Investor Services Pty. Ltd. in Melbourne, Victoria.
For information regarding shares held in the Company, please contact:
Tel: 1 300 850 505 or
Tel: +61 8 9415 4000
Fax: +61 8 9473 2500
For queries go to: www.investorcentre.com/contactus
The Company’s ordinary shares are also traded, via Level II American Depositary Receipts (“ADRs”), on the Nasdaq Capital Market under the ticker GENE. There are 150 ordinary shares comprising each ADR. The Company’s ADR program is maintained by The Bank of New York Mellon in New York, New York.
For information regarding ADRs held in the Company, please contact:
Tel: +1 212 815 2276
Fax: +1 212 571 3050